

## Alberta Drug Benefit List (ADBL) Interim Update now available online

Please be advised that the **May 1, 2025** Updates to the *Alberta Drug Benefit List (ADBL)* have been posted online at [ab.bluecross.ca/dbl/publications.php](http://ab.bluecross.ca/dbl/publications.php).

Please refer to the **May 1, 2025** updates for complete listings of products available by special authorization, step therapy/ special authorization, drug products with changes to benefit status, added products, new established interchangeable groupings, least cost alternative price changes, products with a price change and discontinued listings.

Please note that the online *interactive Drug Benefit List (iDBL)* at [ab.bluecross.ca/dbl/idbl\\_main1.php](http://ab.bluecross.ca/dbl/idbl_main1.php) is a near real-time application, and as such, contains the most up-to-date information.

## Product supply shortage addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross® has confirmed that the shortages for Jamp-Latanoprost/Timolol 0.005%/0.5% Ophthalmic Solution (DIN 02453770), M-Latanoprost/Timolol 0.005%/0.5% Ophthalmic Solution (DIN 02514516), Med-Latanoprost/Timolol 0.005%/0.5% Ophthalmic Solution (DIN 02454505) and Mylan-Latanoprost/Timolol 0.005%/0.5% Ophthalmic Solution (DIN 02373068) have been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA Price Policy will be reapplied to the following grouping effective **June 16, 2025**. The following grouping was removed from the Critical Supply Product List on **May 15, 2025**.

### LATANOPROST / TIMOLOL MALEATE

#### 0.005% / 0.5% OPHTHALMIC SOLUTION

00002436256	ACT LATANOPROST / TIMOLOL	TEV	\$ 4.4268
00002453770	JAMP-LATANOPROST / TIMOLOL	JPC	\$ 4.4268
00002514516	M-LATANOPROST-TIMOLOL	MTR	\$ 4.4268
00002454505	MED-LATANOPROST-TIMOLOL	GMP	\$ 4.4268
00002373068	MYLAN-LATANOPROST / TIMOLOL	MYP	\$ 4.4268
00002246619	XALACOM	BGP	\$ 16.0696

continued next page

*continued from previous page*

## Removal of Temporary Benefit from *Alberta Drug Benefit List (ADBL)*

Due to the unavailability of Cytovene 500 mg/vial Injection (DIN 02162695) manufactured by Cheplapharm Arzneimittel GMBH Germany, **Ganciclovir 500 mg/vial Injection (DIN 02404761)** manufactured by Fresenius Kabi Canada was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Alberta Blue Cross has confirmed that the shortage for Cytovene 500 mg/vial Injection (DIN 02162695) has been resolved.

**Ganciclovir 500 mg/vial Injection (DIN 02404761)** will no longer be considered a temporary benefit for the *ADBL* after **June 16, 2025**. The above grouping was removed from the Critical Supply Product List on **May 14, 2025**.

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct-bill drug claims.

Visit [ab.bluecross.ca/providers/pharmacy-home.php](https://ab.bluecross.ca/providers/pharmacy-home.php)

